J 
Jiangsu Hengrui Pharmaceuticals Co 600276.SS · CNY
Health Care · Pharmaceuticals · Shanghai · 🇨🇳 China
49.23
-2.38%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥31.43bn
FY2016FY2025
Net income
CN¥7.71bn
FY2016FY2025
Free cash flow
CN¥8.32bn
FY2016FY2025
Shareholders' equity
CN¥61.27bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥31.43bn | CN¥27.98bn | CN¥22.82bn | CN¥21.28bn | CN¥25.91bn | CN¥27.73bn | CN¥23.29bn | CN¥17.42bn | CN¥13.84bn | CN¥11.09bn |
| Gross profit | CN¥26.67bn | CN¥24.10bn | CN¥19.26bn | CN¥17.77bn | CN¥22.15bn | CN¥24.38bn | CN¥20.37bn | CN¥15.08bn | CN¥11.98bn | CN¥9.66bn |
| Research and development | CN¥6.67bn | CN¥6.58bn | CN¥4.95bn | CN¥4.89bn | CN¥5.94bn | CN¥4.99bn | CN¥3.90bn | CN¥2.67bn | CN¥1.76bn | CN¥1.18bn |
| Operating income | CN¥8.02bn | CN¥7.49bn | CN¥4.91bn | CN¥4.11bn | CN¥4.66bn | CN¥7.01bn | CN¥6.15bn | CN¥4.60bn | CN¥3.81bn | CN¥3.02bn |
| Net income | CN¥7.71bn | CN¥6.34bn | CN¥4.30bn | CN¥3.91bn | CN¥4.53bn | CN¥6.33bn | CN¥5.33bn | CN¥4.07bn | CN¥3.22bn | CN¥2.59bn |
| Diluted earnings per share | 1.16 | 1.00 | 0.68 | 0.61 | 0.71 | 0.99 | 0.84 | 0.63 | 0.51 | 0.41 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥69.87bn | CN¥50.14bn | CN¥43.78bn | CN¥42.36bn | CN¥39.27bn | CN¥34.73bn | CN¥27.56bn | CN¥22.36bn | CN¥18.04bn | CN¥14.33bn |
| Cash and short-term investments | CN¥41.07bn | CN¥25.09bn | CN¥20.85bn | CN¥17.87bn | CN¥18.72bn | CN¥16.43bn | CN¥13.56bn | CN¥3.89bn | CN¥4.27bn | CN¥4.91bn |
| Total liabilities | CN¥7.69bn | CN¥4.05bn | CN¥2.75bn | CN¥3.94bn | CN¥3.69bn | CN¥3.94bn | CN¥2.62bn | CN¥2.56bn | CN¥2.10bn | CN¥1.46bn |
| Debt | — | CN¥361.0m | CN¥484.9m | CN¥1.81bn | CN¥714.1m | CN¥408.0m | CN¥315.0m | CN¥113.0m | CN¥59.0m | CN¥85.0m |
| Shareholders' equity | CN¥61.27bn | CN¥45.52bn | CN¥40.47bn | CN¥37.82bn | CN¥35.00bn | CN¥30.50bn | CN¥24.78bn | CN¥19.73bn | CN¥15.37bn | CN¥12.39bn |
| Shares outstanding | 6,652m | 6,343m | 6,352m | 6,367m | 6,399m | 6,387m | 6,348m | 6,414m | 6,276m | 6,308m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥11.29bn | CN¥7.42bn | CN¥7.64bn | CN¥1.27bn | CN¥4.22bn | CN¥3.43bn | CN¥3.82bn | CN¥2.77bn | CN¥2.55bn | CN¥2.59bn |
| Capital spending | −CN¥2.96bn | −CN¥1.97bn | −CN¥1.48bn | −CN¥1.99bn | −CN¥1.66bn | −CN¥554.3m | −CN¥561.4m | −CN¥529.1m | −CN¥380.3m | −CN¥1.11bn |
| Free cash flow | CN¥8.32bn | CN¥5.45bn | CN¥6.16bn | −CN¥726.9m | CN¥2.55bn | CN¥2.88bn | CN¥3.26bn | CN¥2.25bn | CN¥2.17bn | CN¥1.48bn |
| Dividends paid | −CN¥1.27bn | −CN¥1.27bn | −CN¥1.02bn | −CN¥1.01bn | −CN¥1.07bn | −CN¥1.02bn | −CN¥810.9m | −CN¥368.2m | −CN¥316.9m | −CN¥195.7m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥7.32bn | CN¥8.14bn | CN¥8.44bn | CN¥7.43bn | CN¥8.56bn | CN¥7.21bn | CN¥7.80bn | CN¥6.59bn |
| Gross profit | CN¥6.29bn | CN¥7.05bn | CN¥7.18bn | CN¥6.35bn | CN¥7.51bn | CN¥6.14bn | CN¥6.75bn | CN¥5.61bn |
| Operating income | CN¥1.67bn | CN¥2.58bn | CN¥2.11bn | CN¥1.28bn | CN¥3.07bn | CN¥2.09bn | CN¥2.15bn | CN¥1.36bn |
| Net income | CN¥2.18bn | CN¥2.28bn | CN¥1.96bn | CN¥1.30bn | CN¥2.58bn | CN¥1.87bn | CN¥1.72bn | CN¥1.19bn |
| Diluted earnings per share | 0.33 | 0.34 | 0.29 | 0.20 | 0.39 | 0.28 | 0.27 | 0.19 |
| Cash from operations | — | — | CN¥2.15bn | CN¥4.81bn | CN¥3.75bn | CN¥573.0m | — | CN¥1.56bn |
| Capital spending | −CN¥872.0m | −CN¥704.0m | −CN¥1.25bn | −CN¥446.0m | −CN¥565.0m | −CN¥702.0m | −CN¥444.0m | −CN¥559.0m |
| Free cash flow | — | — | CN¥899.0m | CN¥4.36bn | CN¥3.19bn | −CN¥129.0m | — | CN¥1.00bn |
| Total assets | CN¥70.77bn | CN¥71.29bn | CN¥69.87bn | CN¥68.33bn | CN¥62.89bn | CN¥51.29bn | CN¥50.14bn | CN¥48.34bn |
| Cash and short-term investments | — | — | CN¥41.07bn | CN¥40.48bn | CN¥36.23bn | CN¥24.20bn | CN¥25.09bn | CN¥22.91bn |
| Debt | — | — | CN¥894.6m | CN¥31.0m | CN¥505.6m | CN¥46.0m | — | — |
| Shareholders' equity | CN¥64.47bn | CN¥63.63bn | CN¥61.27bn | CN¥59.50bn | CN¥58.46bn | CN¥46.99bn | CN¥45.52bn | CN¥43.77bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 13.9% | 2.5% | 12.9% |
| Operating income | 24.9% | 2.7% | 12.1% |
| Net income | 25.4% | 4.0% | 13.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 85.5% | 84.8% | 85.5% | 85.9% |
| Operating margin | 26.1% | 23.7% | 23.0% | 24.3% |
| Net margin | 23.6% | 21.5% | 21.1% | 21.8% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 51.4 | 46.0 | 66.8 | 62.8 | 71.6 | 93.7 | 72.4 | 48.2 | 59.9 | 41.1 |
| Price to sales | 12.6 | 10.4 | 12.6 | 11.5 | 12.5 | 21.4 | 16.6 | 11.2 | 13.9 | 9.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 25 years. Last went ex-dividend on 27 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.20 | 0.20 | 0.20 | 0.16 | 0.16 | 0.167 | 0.16 | 0.127 |
- 6-for-5 split · 10 Jun 2021
- 6-for-5 split · 25 May 2020
- 6-for-5 split · 28 Mar 2019
- 6-for-5 split · 31 May 2017
- 6-for-5 split · 16 Jun 2016
- 11-for-10 split · 15 May 2014
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.